Dietary supplements: FDA may have opportunities to expand its use of reported health problems to oversee products

Dietary Supplements and FDA Use of Adverse Event Reports

Volumn , Issue , 2013, Pages 1-58

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84946944981     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (23)

1. Nutrition Business Journal, NBJ's Supplement Business Report 2012 (Boulder, CO: Penton Media Inc: 2012) at http://newhope360.com/research/supplement-business-report (accessed December 12, 2012).
2. GAO, Dietary Supplements Containing Ephedra: Health Risks and FDA's Oversight, GAO-03- 1042T (Washington, D.C.: July 23, 2003).
3. GAO, Dietary Supplements: FDA Should Take Further Actions to Improve Oversight and Consumer Understanding, GAO-09-250 (Washington, D.C.: Jan. 29, 2009).
4. GAO, Food Safety: Improvements Needed in Overseeing the Safety of Dietary Supplements and "Functional Foods," GAO/RCED-00-156 (Washington, D.C.: July 11, 2000).
5. GAO, FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be Generally Recognized as Safe (GRAS), GAO-10-246 (Washington, D.C.: Feb. 3, 2010) for more information.
6. J.K. Glisson and L.A. Walker, "How physicians should evaluate dietary supplements," American Journal of Medicine 123, No. 7 (2010):577-582.
7. M. Cellini et al., "Dietary Supplements: Physician Knowledge and Adverse Event Reporting," Medicine and Science in Sports and Exercise, 45, No. 1 (2013): 23-28.
8. Department of Health and Human Services, Office of Inspector General, Dietary Supplements: Companies May Be Difficult To Locate in an Emergency (Washington, D.C.: Oct. 2012).
9. The Lewin Group, Final Report on the Value of the Poison Center System, (Falls Church, VA: The Lewin Group: 2012) http://production-aapcc.dotcloud.com/about/lewin-group-report/ (accessed January 7, 2013).
10. National Academy of Sciences, Institute of Medicine, Forging a Poison Prevention and Control System (Washington, D.C.: 2004).
11. Wolkin et al., "Using Poison Center Data for National Public Health Surveillance for Chemical and Poison Exposure and Associated Illness," Annals of Emergency Medicine 59, no. 1 (2011): 56-61.
12. Department of Health and Human Services, Office of Inspector General, Adverse Event Reporting for Dietary Supplements: An Inadequate Safety Valve (Washington, D.C.: April 2001).
13. Haller et al., "Dietary Supplement Adverse Events: Report of a One-Year Poison Center Surveillance Project," Journal of Medical Toxicology 4, no. 2 (2008): 84-92.
14. Department of Health and Human Services, Office of Inspector General, Dietary Supplements: Companies May Be Difficult To Locate in an Emergency (Washington, D.C.: October 2012).
15. Department of Health and Human Services, Office of Inspector General, Adverse Event Reporting for Dietary Supplements: An Inadequate Safety Valve (Washington, D.C.: April 2001).
16. GAO, Managing for Results: Enhancing Agency Use of Performance Information for Management Decision Making, GAO-05-927 (Washington, D.C.: Sept. 9, 2005).
17. OMB, Memorandum for the Heads of Executive Departments and Agencies: Open Government Directive, M-10-06 (Washington, D.C.: Dec. 8, 2009);
18. HHS Open Government Plan Version 2.0 (Washington, D.C.: Apr. 9, 2012);
19. GAO, Information Technology: OMB's Dashboard Has Increased Transparency and Oversight, but Improvements Needed, GAO- 10-701 (Washington, D.C.: July 16, 2010);
20. GAO, Electronic Government Act: Agencies Have Implemented Most Provisions, but Key Areas of Attention Remain,GAO-12-782 (Washington, D.C.: Sept. 12, 2012)
21. Navin K. Kapur and Kiran Musunuru, "Clinical efficacy and safety of statins in managing cardiovascular risk," Vascular Health and Risk Management 4, no. 2 (2008): 341-353
22. Carlo Piccinni et al., "Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting," Diabetes Care 34, no. 6 (2011): 1,369-71.
23. Elisabetta Poluzzi et al., "Antimicrobials and the risk of Torsades de Pointes: The contribution from data mining of the U.S. FDA Adverse Event Reporting System," Drug Safety 33, no. 4 (2010): 303-314.